A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Condition: Advanced Solid Tumors Cancer
Estimated Enrollment: 170
Gender: All
Min Age: 18 Years
Age Group: Adult, Older Adult
Current Status: Recruiting
Study Results: No Results Available
Outcome Measures: Terminal half-life (t1/2) of ABBV-368, Area under the serum concentration-time curve (AUC) of ABBV-368, Maximum tolerated dose (MTD) of ABBV-368 when administered as monotherapy or in combination with ABBV-181, Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181
Interventions: ABBV-368, ABBV-181
Phase:
Study Type: Interventional
Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment
Primary Completion Date: June 15, 2020
Completion Date: September 17, 2020
Last Posted Date: June 10, 2019
Location: Ucsd /Id# 201334, La Jolla, California, United States
Website Link: https://ClinicalTrials.gov/show/NCT03071757